X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (10817) 10817
Patent (2142) 2142
Book Review (1511) 1511
Publication (1072) 1072
Newsletter (296) 296
Book Chapter (159) 159
Conference Proceeding (60) 60
Book / eBook (54) 54
Dissertation (13) 13
Magazine Article (13) 13
Newspaper Article (4) 4
Data Set (3) 3
Government Document (2) 2
Reference (2) 2
Transcript (2) 2
Paper (1) 1
Streaming Video (1) 1
Trade Publication Article (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (8159) 8159
humans (5334) 5334
nucleosides (5218) 5218
nucleotides (2861) 2861
chemistry (2546) 2546
organic chemistry (2371) 2371
nucleic acids (2367) 2367
animals (2243) 2243
sugars (2221) 2221
microbiology (2201) 2201
derivatives thereof (2142) 2142
metallurgy (2142) 2142
biochemistry & molecular biology (2092) 2092
biochemistry (1855) 1855
hiv (1765) 1765
pharmacology & pharmacy (1716) 1716
male (1617) 1617
female (1556) 1556
enzymology (1508) 1508
beer (1480) 1480
mutation or genetic engineering (1478) 1478
spirits (1478) 1478
vinegar (1478) 1478
wine (1478) 1478
hiv infections - drug therapy (1462) 1462
infectious diseases (1369) 1369
nucleoside analogs (1327) 1327
antiviral agents (1290) 1290
virology (1245) 1245
culture media (1126) 1126
compositions thereof (1104) 1104
microorganisms or enzymes (1104) 1104
propagating, preserving or maintaining microorganisms (1104) 1104
adult (1100) 1100
hiv-1 - drug effects (1078) 1078
analysis (1047) 1047
mutation (1046) 1046
human necessities (986) 986
chemistry, organic (966) 966
dna (957) 957
research (930) 930
hygiene (928) 928
medical or veterinary science (928) 928
antiretroviral therapy (903) 903
preparations for medical, dental, or toilet purposes (902) 902
immunology (876) 876
middle aged (847) 847
aids/hiv (837) 837
anti-hiv agents - pharmacology (821) 821
compositions or test papers therefor (816) 816
condition-responsive control in microbiological orenzymological processes (816) 816
measuring or testing processes involving enzymes, nucleicacids or microorganisms (816) 816
processes of preparing such compositions (816) 816
enzymes (814) 814
reverse transcriptase inhibitors - pharmacology (810) 810
drug resistance (801) 801
nucleoside (796) 796
chemistry, medicinal (793) 793
human-immunodeficiency-virus (789) 789
mice (770) 770
protease inhibitors (720) 720
cell line (716) 716
drug therapy (697) 697
anti-hiv agents - therapeutic use (684) 684
antiviral agents - pharmacology (679) 679
fermentation or enzyme-using processes to synthesise a desiredchemical compound or composition or to separate optical isomersfrom a racemic mixture (678) 678
reverse transcriptase inhibitors - therapeutic use (674) 674
dna polymerases (656) 656
reverse-transcriptase (654) 654
rna (648) 648
human immunodeficiency virus--hiv (645) 645
molecular sequence data (636) 636
proteins (629) 629
reverse-transcriptase inhibitors (629) 629
kinetics (628) 628
non-nucleoside reverse transcriptase inhibitors (624) 624
peptides (623) 623
health aspects (620) 620
aids (616) 616
hiv-1 - genetics (609) 609
therapy (609) 609
hiv infections - virology (605) 605
article (602) 602
nucleoside reverse transcriptase inhibitors (602) 602
in-vitro (595) 595
nucleosides - chemistry (589) 589
antiretroviral drugs (581) 581
immunodeficiency-virus type-1 (572) 572
lamivudine (563) 563
hiv-1 (556) 556
analogs (542) 542
derivatives (540) 540
specific therapeutic activity of chemical compounds ormedicinal preparations (539) 539
cancer (536) 536
nucleosides - pharmacology (536) 536
infection (534) 534
structure-activity relationship (534) 534
models, molecular (533) 533
zidovudine (531) 531
molecular structure (521) 521
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (30) 30
UofT at Mississauga - Stacks (7) 7
Chemistry (A D Allen) - Stacks (6) 6
Collection Dvlpm't (Acquisitions) - Closed Orders (5) 5
UTL at Downsview - May be requested (4) 4
Collection Dvlpm't (Acquisitions) - Vendor file (3) 3
Collection Dvlpm't (Acquisitions) - Cancelled Order (1) 1
Gerstein Science - Circulation Desk (1) 1
Law (Bora Laskin) - Stacks (1) 1
New College (Ivey) - Stacks (1) 1
Online Resources - Online (1) 1
Robarts - Stacks (1) 1
UofT at Scarborough - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (13124) 13124
French (609) 609
Chinese (247) 247
German (186) 186
Spanish (78) 78
Russian (53) 53
Japanese (38) 38
Korean (30) 30
Norwegian (26) 26
Portuguese (21) 21
Danish (7) 7
Czech (6) 6
Italian (5) 5
Romanian (4) 4
Turkish (4) 4
Dutch (3) 3
Finnish (3) 3
Hungarian (3) 3
Icelandic (3) 3
Polish (3) 3
Croatian (2) 2
Slovenian (2) 2
Swedish (2) 2
Arabic (1) 1
Estonian (1) 1
Greek (1) 1
Hebrew (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


HIV Medicine, ISSN 1464-2662, 11/2008, Volume 9, Issue 10, pp. 883 - 896
Journal Article
Journal of Biological Chemistry, ISSN 0021-9258, 12/2009, Volume 284, Issue 51, pp. 35681 - 35691
Journal Article
The Journal of Infectious Diseases, ISSN 0022-1899, 5/2009, Volume 199, Issue 9, pp. 1275 - 1285
Journal Article
The Journal of Infectious Diseases, ISSN 0022-1899, 10/2007, Volume 196, Issue 8, pp. 1180 - 1190
Journal Article
PLOS ONE, ISSN 1932-6203, 02/2017, Volume 12, Issue 2, pp. e0171596 - e0171596
Objectives Two nucleos(t) ide reverse-transcriptase inhibitors (NRTIs) plus 1 non-NRTI (nNRTI) remain the preferred or alternative combination antiretroviral... 
TRANSMITTED DRUG-RESISTANCE | RISK-FACTORS | VIRUS-INFECTION | MULTIDISCIPLINARY SCIENCES | CLINICAL-TRIALS | INFECTED PATIENTS | HIV-1-INFECTED PATIENTS | NEVIRAPINE USE | HEPATITIS-C | ADVERSE EVENTS | PROTEASE INHIBITORS | Humans | Middle Aged | Male | RNA, Viral - blood | Alanine Transaminase - blood | Viral Load | Incidence | Reverse Transcriptase Inhibitors - adverse effects | Young Adult | Adult | Anti-HIV Agents - therapeutic use | Female | Retrospective Studies | Reverse Transcriptase Inhibitors - therapeutic use | Drug Therapy, Combination | Chemical and Drug Induced Liver Injury - enzymology | Chemical and Drug Induced Liver Injury - etiology | Severity of Illness Index | Drug Eruptions - etiology | Nucleosides - therapeutic use | Anti-HIV Agents - adverse effects | Risk Factors | Chemical and Drug Induced Liver Injury - epidemiology | CD4 Lymphocyte Count | Nucleosides - adverse effects | Viremia - drug therapy | Aspartate Aminotransferases - blood | Taiwan - epidemiology | HIV Infections - drug therapy | Disease Management | Drug Eruptions - epidemiology | Nevirapine | Toxicity | Exanthema | Viruses | Drug resistance | Efavirenz | Confidence intervals | Hepatitis | Acquired immune deficiency syndrome--AIDS | Antiretroviral agents | Human immunodeficiency virus--HIV | Division | Hepatitis B virus | Hepatotoxicity | Antiretroviral drugs | Hepatitis B surface antigen | Statistical analysis | Regression analysis | Ribonucleic acid--RNA | Patients | Antiretroviral therapy | CD4 antigen | Inhibitors | Protease inhibitors | Womens health | Nucleosides | Skin | Hepatitis C virus | Hepatitis C | Index Medicus | RNA | Acquired immune deficiency syndrome | Ribonucleic acid | AIDS | HIV | Human immunodeficiency virus
Journal Article
Journal of Adolescent Health, ISSN 1054-139X, 2015, Volume 58, Issue 4, pp. 451 - 459
Journal Article
Science, ISSN 0036-8075, 11/2014, Volume 346, Issue 6212, pp. 1000 - 1003
Nucleoside reverse transcriptase inhibitors (NRTIs) are mainstay therapeutics for HIV that block retrovirus replication. Alu (an endogenous retroelement that... 
P2X7 RECEPTOR | PATHOGENESIS | INTERLEUKIN-18 | P2X RECEPTOR | INFLAMMASOME ACTIVATION | MULTIDISCIPLINARY SCIENCES | MACULAR DEGENERATION | NLRP3 INFLAMMASOME | ATP RELEASE | VERSUS-HOST-DISEASE | CASPASE-1 ACTIVATION | Retinal Pigment Epithelium - metabolism | Apoptosis - drug effects | NLR Family, Pyrin Domain-Containing 3 Protein | Reverse Transcriptase Inhibitors - pharmacology | Caspase 1 - metabolism | Geographic Atrophy - drug therapy | Anti-Inflammatory Agents, Non-Steroidal - pharmacology | Hepatitis - drug therapy | Animals | Carrier Proteins - metabolism | Choroidal Neovascularization - drug therapy | Graft vs Host Disease - drug therapy | Inflammasomes - drug effects | Liver - drug effects | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Retinal Pigment Epithelium - physiology | Receptors, Purinergic P2X7 - metabolism | Mice | Reverse Transcriptase Inhibitors - therapeutic use | Alu Elements | Disease Models, Animal | Retinal Pigment Epithelium - drug effects | Prevention | Genetic research | Genetic aspects | Genetic transcription | Research | HIV (Viruses) | Virus research | Macular degeneration | Inhibitor drugs | Drug therapy | Ribonucleic acid--RNA | Human immunodeficiency virus--HIV | Index Medicus | Atrophy | Drugs | Inhibitors | Ribonucleic acids | Blocking | Nucleosides | Activation | Grafting
Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9787, pp. 229 - 237
Summary Background The non-nucleoside reverse transcriptase inhibitor (NNRTI), rilpivirine (TMC278; Tibotec Pharmaceuticals, County Cork, Ireland), had... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | ZIDOVUDINE | COMBINATION THERAPY | ACTIVE ANTIRETROVIRAL THERAPY | EMTRICITABINE | PROTEASE-INHIBITOR | CYSTATIN-C | CREATININE | DAILY LAMIVUDINE | NEVIRAPINE | TENOFOVIR | Rilpivirine | HIV Reverse Transcriptase - antagonists & inhibitors | Humans | Middle Aged | Male | Anti-HIV Agents - administration & dosage | Nitriles - administration & dosage | Tenofovir | Deoxycytidine - therapeutic use | Nucleotides - therapeutic use | Adenine - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Reverse Transcriptase Inhibitors - therapeutic use | Acquired Immunodeficiency Syndrome - virology | Acquired Immunodeficiency Syndrome - ethnology | Emtricitabine | Nucleosides - therapeutic use | Adenine - analogs & derivatives | Benzoxazines - administration & dosage | Double-Blind Method | Drug Administration Schedule | Organophosphonates - therapeutic use | HIV-1 - drug effects | Pyrimidines - administration & dosage | Anti-HIV Agents - adverse effects | Benzoxazines - adverse effects | Treatment Outcome | HIV-1 - genetics | Acquired Immunodeficiency Syndrome - drug therapy | Benzoxazines - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Mutation | Nitriles - adverse effects | Viral Load - drug effects | Deoxycytidine - analogs & derivatives | Nitriles - therapeutic use | Evaluation | Patient outcomes | Clinical trials | Dosage and administration | Drug therapy | HIV infection | Design | Antiretroviral drugs | Corporate sponsorship | Human immunodeficiency virus--HIV | Technological change | Research | Clinical medicine | Drugs | RNA-directed DNA polymerase | Exanthema | antiretroviral therapy | Lamivudine | Lipids | Nucleotides | Regression analysis | Efavirenz | CD4 antigen | nucleosides | Algorithms | Hospitals | non-nucleoside reverse transcriptase inhibitors | Abacavir | Zidovudine | Pharmaceuticals | Index Medicus | Abridged Index Medicus
Journal Article